A role for oncostatin M in inflammatory bowel disease

被引：23
作者：
Kim, Walter M. [1 ]
Kaser, Arthur [2 ]
Blumberg, Richard S. [1 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Gastroenterol, Boston, MA 02115 USA
[2] Univ Cambridge, Dept Med, Div Gastroenterol & Hepatol, Cambridge, England
来源：
NATURE MEDICINE | 2017年 / 23卷 / 05期
关键词：
MAINTENANCE THERAPY; ULCERATIVE-COLITIS; CROHNS-DISEASE; INDUCTION; VEDOLIZUMAB;
D O I：
10.1038/nm.4338
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
A new study identifies oncostatin M (OSM) as a potential biomarker and therapeutic target for anti-tumor necrosis factor (TNF)-refractory inflammatory bowel disease (IBD), and pinpoints mucosal stromal cells as key players in OSM-mediated inflammation.
引用
收藏
页码：535 / 536
页数：2
相关论文
共 50 条
  • [1] Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis
    Yang, Yue
    Fu, Kan-Zuo
    Pan, Gu
    WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2024, 16 (01):
  • [2] Oncostatin-M Does Not Predict Treatment Response in Inflammatory Bowel Disease in a Pediatric Cohort
    Ladipo, Jennifer Ezirike
    He, Zhaoping
    Chikwava, Kudakwashe
    Robbins, Katherine
    Beri, Jonathan
    Molle-Rios, Zarela
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2021, 73 (03) : 352 - 357
  • [3] The role of integrin antagonists in the treatment of inflammatory bowel disease
    Beniwal-Patel, Poonam
    Saha, Sumona
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (12) : 1815 - 1823
  • [4] Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease
    Verstockt, Sare
    Verstockt, Bram
    Machiels, Kathleen
    Vancamelbeke, Maaike
    Ferrante, Marc
    Cleynen, Isabelle
    De Hertogh, Gert
    Vermeire, Severine
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (10) : 1564 - 1575
  • [5] Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease measured by chemiluminescence immunoassay
    Cao, Ying
    Dai, Yibei
    Zhang, Lingyu
    Wang, Danhua
    Yu, Qiao
    Hu, Wen
    Wang, Xuchu
    Yu, Pan
    Ping, Ying
    Sun, Tao
    Sang, Yiwen
    Liu, Zhenping
    Chen, Yan
    Tao, Zhihua
    CLINICAL BIOCHEMISTRY, 2022, 100 : 35 - 41
  • [6] VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Haddley, K.
    DRUGS OF TODAY, 2014, 50 (04) : 309 - 319
  • [7] Update: chronic inflammatory Bowel Disease
    Atreya, Raja
    Neumann, Helmut
    Neurath, Markus Friedrich
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2015, 140 (23) : 1762 - U100
  • [8] Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD)
    Verstockt, Sare
    Verstockt, Bram
    Vermeire, Severine
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (11) : 943 - 954
  • [9] The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease
    Gupta, Nancy
    Papasotiriou, Sam
    Hanauer, Stephen
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2023, 19 (09) : 1075 - 1089
  • [10] Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment
    Calvino-Suarez, Cristina
    Ferreiro-Iglesias, Rocio
    Baston-Rey, Iria
    Barreiro-de Acosta, Manuel
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (13)
12345